Point of care biosensor to improve diagnostics of diseases associated with a dysregulation of the immune system
Market Maturity: Exploring
These are innovations that are actively exploring value creation opportunities. Learn more
Market Creation Potential
This innovation was assessed by the JRC’s Market Creation Potential indicator framework as having a “Noteworthy” level of Market Creation Potential. Only innovations that are showing multiple signals of market creation potential are assigned a value under this indicator system. Learn more
A woman had a leadership role in developing this innovation in at least one of the Key Innovator organisations listed below.
Go to Market needs
Needs that, if addressed, can increase the chances this innovation gets to (or closer to) the market incude:
Prepare for Market entry
Scale-up market opportunities
Location of Key Innovators developing this innovation
Stichting Sanquin Bloedvoorziening
AMSTERDAM, NL Higher Education Institute / Research Centre
REGENSBURG, DE Higher Education Institute / Research Centre
MICROCOAT BIOTECHNOLOGIE GMBH
BERNRIED, DE Small or Medium Enterprise
The EU-funded Research Project
This innovation was developed under the Horizon 2020 project SciFiMed with an end date of 31/12/2024
This transdisciplinary project will combine fundamental immunological research with novel nanomaterial-based biosensor development translated into proof-of-principle diagnostics to revolutionize doctors’ ability to diagnose and treat severe diseases plaguing millions of Europeans.
Impaired defence against infections, incurable renal, eye and autoimmune diseases represent a huge burden on human health and consequently cost our society not only personal suffering but also hundreds of billions of Euros p.a.. All of these diseases share an association with a dysregulation of the complement system, a major effector of the innate immune system. There still is a huge discrepancy between what we know and what we need to know about the complement system’s role in these diseases in order to prevent, diagnose and treat them appropriately, effectively, and efficiently .
Complement factor H (FH) and FH-related (FHR) proteins are strongly associated with these systemic and organ-specific pathologies. In contrast to FH, the function of the remaining six highly homologous FHR proteins is mostly unknown and, hence, their role in the different disease-specific pathogenic mechanisms remain elusive.
Our EU consortium (8 partners from 4 countries) will unravel the mysteries of the FH-protein family’s contributions to diseases. Then, via an ambitious and transdisciplinary fundamental science-to-technology transfer, a proof-of-principle for a multiplex detection system will be developed to simultaneously quantify and analyse the functional activity of all seven FH-protein family members in patient samples – on site, putting diagnostic technology directly into physicians’ hands.
In the future, this high-impact project propels immunological research in Europe, enables new product development of bioanalytical companies, modernizes the EU-diagnostic market and provides new perspectives for patient treatment, which in turn will pave the way for novel approaches for drug development.
Innnovation Radar's analysis of this innovation is based on data collected on 25/02/2022.